Shoreline Biosciences v. Fate Therapeutics: Federal Circuit Appeal Voluntarily Dismissed
Shoreline Biosciences brought a Federal Circuit appeal against Fate Therapeutics and the Whitehead Institute for Biomedical Research over seven patents covering somatic cell reprogramming compositions and methods. The parties jointly agreed to dismiss the appeal under Fed. R. App. P. 42(b) after 386 days — leaving the merits unresolved at the appellate level.
Seven cell reprogramming patents, one agreed Federal Circuit exit
Shoreline Biosciences, Inc. filed Case No. 24-1055 at the Court of Appeals for the Federal Circuit on October 17, 2023, appealing an infringement action against Fate Therapeutics, Inc. and the Whitehead Institute for Biomedical Research. The dispute centred on seven US patents — US10457917B2, US8071369B2, US9169490B2, US8951797B2, US8940536B2, US10017744B2, and US8932856B2 — covering compositions and methods for identifying reprogramming factors, reprogramming somatic cells, and making somatic cells more susceptible to reprogramming.
The appeal was closed on November 6, 2024, after just 386 days, when the parties jointly agreed to dismiss the proceeding under Federal Rule of Appellate Procedure 42(b). The court’s order reflects mutual consent rather than any adjudication on the merits. Because the basis of termination is recorded as ‘Voluntary dismissal’ without specifying whether the dismissal was with or without prejudice, the public record is silent on that critical distinction — a point with significant implications for potential future litigation.
A joint voluntary dismissal at the Federal Circuit level — particularly across a portfolio of seven patents — typically signals a negotiated resolution between sophisticated parties, possibly including a licence, cross-licence, or commercial settlement, though none of these can be confirmed from the public docket. The relatively swift resolution compared to the complexity of a seven-patent appellate case is commercially notable. What remains unknown is whether Shoreline retains the right to re-assert these patents, and whether any underlying district court judgments remain in force.
Filing to Voluntary dismissal in 386 days
386 days — from Federal Circuit filing to joint dismissal order
Appeal voluntarily dismissed: what the agreed order means for both parties
Fed. R. App. P. 42(b): what a joint appellate dismissal means
Under Federal Rule of Appellate Procedure 42(b), parties may stipulate to dismiss an appeal at any time. The court’s order here reflects exactly that: both sides agreed, and the Federal Circuit issued no ruling on the merits. This is a procedural exit — not an affirmance, reversal, or vacatur. The underlying legal questions about patent validity and infringement remain unanswered by this court.
No merits adjudicationWith or without prejudice? The public record is silent
A voluntary dismissal ‘with prejudice’ bars the dismissing party from refiling the same claims; ‘without prejudice’ preserves that right. The basis of termination here is recorded simply as ‘Voluntary dismissal’ — the public docket does not specify which applies. This distinction is material: Shoreline’s ability to re-assert these seven reprogramming patents against Fate or Whitehead in future proceedings may hinge on an agreement term not visible in the public record.
Prejudice unconfirmedShoreline exits without a Federal Circuit ruling on its patent portfolio
Shoreline Biosciences secured no appellate vindication for its seven reprogramming patents in this proceeding. A joint dismissal does not signal weakness per se — it may reflect a negotiated commercial outcome — but Shoreline receives no precedential ruling that strengthens its patent portfolio’s enforceability. The value of any private resolution depends entirely on terms not in the public record.
No appellate win on recordFate Therapeutics and Whitehead face no Federal Circuit adverse ruling
The dismissal means Fate Therapeutics and the Whitehead Institute carry no Federal Circuit finding of infringement or validity against them in this matter. However, the absence of a merits ruling also means the challenged patents were not invalidated at this level. Competitors and licensees in the iPSC and somatic cell reprogramming space cannot rely on this dismissal as evidence of patent weakness — the portfolio remains legally intact.
No invalidity ruling securedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Shoreline Biosciences, Inc. | Company | Cell therapy biosciences company — holder of US10457917B2 and 6 related reprogramming patentsSearch in Eureka ↗ |
| Defendant | Fate Therapeutics, Inc. | Company | Fate Therapeutics (cell therapy developer) and Whitehead Institute for Biomedical Research (biomedical research institution)Search in Eureka ↗ |
| Co-Defendant | Whitehead Institute For Biomedical Research | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Eric M. Acker, Esq. | Attorney | Counsel for Shoreline Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster, LLP | Law Firm | Representing Shoreline Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Joseph Thomas Ergastolo | Attorney | Counsel for Fate Therapeutics, Inc.Search in Eureka ↗ |
| Defendant law firm | Wright, L’estrange & Ergastolo | Law Firm | Representing Fate Therapeutics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge e Marilyn L. Huff | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order adopts the language of the parties’ stipulation verbatim: the proceeding is ‘DISMISSED under Fed. R. App. P. 42(b).’ This phrasing is purely procedural — it carries no assessment of patent validity, claim scope, or infringement. Because the court issued no substantive ruling, neither party can invoke this order as precedent. The dismissal does not disturb any lower-court findings that may exist in the underlying record, and the seven asserted patents remain in force as granted.
US10457917B2 and 6 related patents — somatic cell reprogramming portfolio
The seven patents at the centre of this dispute collectively cover a foundational area of cell biology: the reprogramming of somatic (non-reproductive) cells into pluripotent stem cells. The portfolio spans compositions for identifying the molecular factors that trigger reprogramming, formulations for delivering those factors, and methods for enhancing cellular susceptibility to the reprogramming process. Application dates across the family — ranging from US12/703015 to US16/030815 — suggest a multi-year prosecution strategy designed to build layered claim coverage around an iPSC-related technology platform.
Induced pluripotent stem cell (iPSC) technology is foundational to next-generation cell therapy pipelines, including the NK-cell and T-cell programmes that both Shoreline Biosciences and Fate Therapeutics are known to pursue. A portfolio that controls upstream reprogramming compositions and methods therefore represents significant commercial leverage — any competitor or academic institution working in allogeneic cell therapy must assess whether their iPSC derivation workflows fall within the scope of these claims. The absence of an invalidity ruling in this case means the portfolio retains full enforceability.
Should your iPSC programme run an FTO against this 7-patent portfolio?
Any organisation developing iPSC-derived cell therapies — including allogeneic NK, T-cell, or macrophage products — should treat this portfolio as a live freedom-to-operate risk. The patents span multiple claim types: composition claims covering reprogramming factor combinations, method claims covering reprogramming workflows, and susceptibility-enhancement claims that could capture pre-conditioning steps used broadly across the field. The lack of an invalidity ruling in this case means none of these patents have been judicially weakened.
PatSnap Eureka’s FTO Search Agent can map each of the seven asserted patents against your specific cell reprogramming protocols — identifying overlapping claim language, prosecution history estoppel positions, and prior art landscapes for each grant. Eureka can also surface continuation or continuation-in-part applications from the same families, flagging future claim risk before it materialises. For R&D teams designing iPSC workflows, an early FTO against this portfolio is a commercial priority.
Run a freedom-to-operate analysis on US10457917B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in iPSC and cell reprogramming patent disputes
Federal Circuit cases involving iPSC technology, somatic cell reprogramming patents, and cell therapy platform IP — voluntarily dismissed or otherwise resolved at appellate level.
What this case signals for the cell reprogramming and iPSC IP landscape
A seven-patent Federal Circuit appeal ending by joint consent raises pointed questions about patent strategy and commercial leverage in the competitive iPSC therapeutics sector.
Seven-patent portfolios command settlement leverage even at appeal stage
The breadth of Shoreline’s asserted portfolio — spanning compositions, methods, and susceptibility-enhancement techniques — suggests a layered assertion strategy. Asserting multiple patents covering adjacent aspects of a single technology area raises the cost and risk of litigation for defendants, potentially accelerating resolution. Companies in the cell therapy space should audit their own freedom-to-operate against each of these seven patents individually.
Joint dismissals at the Federal Circuit often signal private licensing outcomes
A mutual agreement to dismiss under Rule 42(b) — particularly after a case has progressed to appellate briefing — is consistent with a negotiated licence or commercial settlement. For IP professionals, this pattern suggests the patents held sufficient perceived validity and infringement risk to motivate resolution without a ruling. The absence of a public licence term makes competitive benchmarking difficult but does not neutralise the portfolio’s threat.
Shoreline v Fate — key questions answered
The Federal Circuit appeal was voluntarily dismissed by agreement of all parties under Fed. R. App. P. 42(b) on November 6, 2024, after 386 days. No merits ruling was issued. The case involved seven US patents covering somatic cell reprogramming compositions and methods asserted by Shoreline Biosciences against Fate Therapeutics and the Whitehead Institute for Biomedical Research.
Shoreline asserted seven US patents: US10457917B2, US8071369B2, US9169490B2, US8951797B2, US8940536B2, US10017744B2, and US8932856B2. These patents collectively cover compositions for identifying reprogramming factors, compositions for reprogramming somatic cells, methods for enhancing cellular susceptibility to reprogramming, and methods for reprogramming somatic cells.
The public record does not specify. The basis of termination is recorded as ‘Voluntary dismissal’ without indicating whether it was with or without prejudice. A dismissal with prejudice would bar Shoreline from re-asserting the same claims against these defendants, while a dismissal without prejudice would preserve that option. The distinction likely turns on private agreement terms not visible in the public docket.
No. A procedural dismissal under Fed. R. App. P. 42(b) carries no merits determination. The Federal Circuit issued no ruling on patent validity or infringement. All seven asserted patents — US10457917B2 and the six related grants — remain in force as granted and cannot be considered judicially weakened by this dismissal.
The Whitehead Institute’s presence as a co-defendant alongside Fate Therapeutics suggests the infringement claims may have implicated technology originating from or co-owned by the Institute — a pattern common in translational biotech disputes where academic foundational IP underpins commercial cell therapy programmes. The dismissal resolved the appeal without any ruling on the Institute’s liability or the validity of any institutional IP rights.
PatSnap Eureka searches patents and litigation data to answer instantly.